Publications by authors named "K Addonizio"

Objectives: Belatacept may provide benefit in delayed graft function, but its association with infectious complications is understudied. We aim to assess the incidence of CMV and BK viremia in patients treated with sirolimus or belatacept as part of a three-drug immunosuppression regimen after kidney transplantation.

Materials And Methods: Kidney transplant recipients from 01/01/2015 to 10/01/2021 were retrospectively reviewed.

View Article and Find Full Text PDF

Background: Belatacept is employed alongside calcineurin inhibitor (CNI) therapy to prevent graft rejection in kidney transplant patients who are Epstein-Barr virus (EBV) seropositive. Preliminary data suggested that rates of post-transplant lymphoproliferative disorder (PTLD) were higher in individuals treated with belatacept compared to CNI therapy alone.

Methods: The records of 354 adults who underwent kidney only transplantation from January 2015 through September 2021 at one medical center were evaluated.

View Article and Find Full Text PDF

Diagnosis of pyruvate kinase deficiency (PKD), the most common cause of hereditary non-spherocytic haemolytic anaemia, remains challenging in routine practice and no biomarkers for clinical severity have been characterised. This prospective study enrolled 41 patients with molecularly confirmed PKD from nine North American centres to evaluate the diagnostic sensitivity of pyruvate kinase (PK) enzyme activity and PK:hexokinase (HK) enzyme activity ratio, and evaluate the erythrocyte PK (PK-R) protein level and erythrocyte metabolites as biomarkers for clinical severity. In this population not transfused for ≥90 days before sampling, the diagnostic sensitivity of the PK enzyme assay was 90% [95% confidence interval (CI) 77-97%], whereas the PK:HK ratio sensitivity was 98% (95% CI 87-100%).

View Article and Find Full Text PDF
Article Synopsis
  • Pyruvate kinase (PK) deficiency is a rare genetic blood disorder caused by mutations in the PKLR gene; this study analyzed the genetic features of 257 patients.
  • A total of 127 pathogenic variants were identified, with significant findings including the most common mutations being p.R510Q and p.R486W, and 21% of patients having previously unreported variants.
  • Patients with certain mutations exhibited more severe symptoms and complications, including lower hemoglobin levels and higher rates of serious health issues, while pregnancy outcomes were consistent across different genetic backgrounds.
View Article and Find Full Text PDF